Differentiating Oncocytic Renal Tumors from Chromophobe Renal Cell Carcinoma: Comparison of Peak Early-phase Enhancement Ratio to Clinical Risk Factors and Rater Predictions

Overview

Journal Eur Urol Open Sci

Date 2022 Dec 12

PMID 36506255

Authors

Hiten D Patel

Kevin Huai

Nicholas Elliott

Deanna L Thorson

Goran Rac

Maria M Picken

Marcus L Quek

Davide Bova

Gopal N Gupta

Affiliations

Soon will be listed here.

Abstract

Background: Most surgically resected benign renal tumors are found to be oncocytomas or indolent hybrid oncocytic tumors, which are difficult to differentiate from chromophobe renal cell carcinoma (chRCC) on renal mass biopsy. Both often exhibit CD117 staining.

Objective: To evaluate the ability of the peak early-phase enhancement ratio (PEER) to distinguish oncocytomas from chRCC and compare its discrimination to traditional clinical risk factors and blinded clinical raters.

Design Setting And Participants: This was a diagnostic case-control study of patients (2006-2020) with oncocytoma or chRCC according to surgical pathology.

Intervention: Partial or radical nephrectomy.

Outcome Measurements And Statistical Analysis: Three clinical raters blinded to histology measured the PEER and the presence of stellate scar and predicted the final histology for each tumor. Averaged and individual PEER values were compared to surgical pathology and assessed for interobserver variability. Subanalyses were conducted for patients with confirmed CD117 status.

Results And Limitations: For the 76 patients identified, PEER was higher among the 32 (42.1%) oncocytomas than among the 44 (57.9%) chRCCs (median 0.81 vs 0.43; < 0.001), with high correlation across raters (correlation coefficients ≥0.85). A PEER cutoff of <0.60 was strongly associated with identification of chRCC (OR 95.7 (95% CI 19.9-460.8), < 0.001). In the overall and CD117 cohorts, sensitivity was 93.2% and 97.0%, the negative predictive value was 90.3% and 95.5%, and the area under the receiver operating characteristic curve (AUC) on multivariable modeling was 95.0% and 98.1%, respectively. PEER outperformed models with clinical risk factors alone (AUC 70.4%) and histology predictions by three raters (AUC 51.6%, 62.5%, and 63.1%). Limitations include reliance on surgical pathology and inclusion of a mix of early contrast-enhanced phases.

Conclusions: PEER reliably differentiated benign renal oncocytomas and indolent hybrid tumors from malignant chRCC with excellent diagnostic performance. A diagnostic pathway with biopsy, CD117 staining, and PEER deserves further study to potentially avoid unnecessary surgery for oncocytic renal tumors.

Patient Summary: We assessed a measurement called PEER on computed tomography (CT) scans and found higher values for benign and lower values for malignant kidney masses, so we were able to tell these apart. PEER was reliable for identifying tumors with positive staining for the CD117 protein biomarker as well as in the overall patient group. Our results show that PEER could be considered for use with biopsy and CD117 staining to potentially avoid unnecessary surgery for benign kidney masses.

References

Su Z, Patel H, Huang M, Meyer A, Pavlovich C, Pierorazio P . Cost-effectiveness Analysis of Tc-sestamibi SPECT/CT to Guide Management of Small Renal Masses. Eur Urol Focus. 2020; 7(4):827-834. DOI: 10.1016/j.euf.2020.02.010. View

Amin J, Xu B, Badkhshan S, Creighton T, Abbotoy D, Murekeyisoni C . Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma. Clin Cancer Res. 2018; 24(16):3898-3907. PMC: 7951998. DOI: 10.1158/1078-0432.CCR-18-0252. View

Patel H, Gupta M, Joice G, Srivastava A, Alam R, Allaf M . Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States. Eur Urol Oncol. 2019; 2(4):343-348. DOI: 10.1016/j.euo.2018.08.023. View

Metcalf M, Cheaib J, Biles M, Patel H, Pena V, Chang P . Outcomes of Active Surveillance for Young Patients with Small Renal Masses: Prospective Data from the DISSRM Registry. J Urol. 2020; 205(5):1286-1293. DOI: 10.1097/JU.0000000000001575. View

Patel H, Semerjian A, Gupta M, Pavlovich C, Johnson M, Gorin M . Surgical removal of renal tumors with low metastatic potential based on clinical radiographic size: A systematic review of the literature. Urol Oncol. 2019; 37(8):519-524. DOI: 10.1016/j.urolonc.2019.05.013. View

Wobker S, Williamson S . Modern Pathologic Diagnosis of Renal Oncocytoma. J Kidney Cancer VHL. 2017; 4(4):1-12. PMC: 5634396. DOI: 10.15586/jkcvhl.2017.96. View

Flack C, Calaway A, Miller B, Picken M, Gondim D, Idrees M . Comparing oncologic outcomes in patients undergoing surgery for oncocytic neoplasms, conventional oncocytoma, and chromophobe renal cell carcinoma. Urol Oncol. 2019; 37(11):811.e17-811.e21. DOI: 10.1016/j.urolonc.2019.06.002. View

Alam R, Patel H, Osumah T, Srivastava A, Gorin M, Johnson M . Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study. BJU Int. 2018; 123(1):42-50. PMC: 6301094. DOI: 10.1111/bju.14490. View

Patel H, Johnson M, Pierorazio P, Sozio S, Sharma R, Iyoha E . Diagnostic Accuracy and Risks of Biopsy in the Diagnosis of a Renal Mass Suspicious for Localized Renal Cell Carcinoma: Systematic Review of the Literature. J Urol. 2016; 195(5):1340-1347. PMC: 5609078. DOI: 10.1016/j.juro.2015.11.029. View

10.

Welch H, Skinner J, Schroeck F, Zhou W, Black W . Regional Variation of Computed Tomographic Imaging in the United States and the Risk of Nephrectomy. JAMA Intern Med. 2017; 178(2):221-227. PMC: 5838611. DOI: 10.1001/jamainternmed.2017.7508. View

11.

Patel H, Druskin S, Rowe S, Pierorazio P, Gorin M, Allaf M . Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis. BJU Int. 2017; 119(5):661-666. DOI: 10.1111/bju.13763. View

12.

Pierorazio P, Patel H, Johnson M, Sozio S, Sharma R, Iyoha E . Distinguishing malignant and benign renal masses with composite models and nomograms: A systematic review and meta-analysis of clinically localized renal masses suspicious for malignancy. Cancer. 2016; 122(21):3267-3276. DOI: 10.1002/cncr.30268. View

13.

Menon A, Hussein A, Attwood K, White T, James G, Xu B . Active Surveillance for Risk Stratification of All Small Renal Masses Lacking Predefined Clinical Criteria for Intervention. J Urol. 2021; 206(2):229-239. PMC: 9036570. DOI: 10.1097/JU.0000000000001714. View

14.

Trpkov K, Williamson S, Gill A, Adeniran A, Agaimy A, Alaghehbandan R . Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol. 2021; 34(6):1167-1184. DOI: 10.1038/s41379-021-00737-6. View

15.

Patel H, Nichols P, Su Z, Gupta M, Cheaib J, Allaf M . Renal Mass Biopsy is Associated with Reduction in Surgery for Early-Stage Kidney Cancer. Urology. 2019; 135:76-81. DOI: 10.1016/j.urology.2019.08.043. View

16.

Amin M, McKenney J, Martignoni G, Campbell S, Pal S, Tickoo S . Low grade oncocytic tumors of the kidney: a clinically relevant approach for the workup and accurate diagnosis. Mod Pathol. 2022; 35(10):1306-1316. DOI: 10.1038/s41379-022-01108-5. View

17.

Kim J, Li S, Khandwala Y, Chung K, Park H, Chung B . Association of Prevalence of Benign Pathologic Findings After Partial Nephrectomy With Preoperative Imaging Patterns in the United States From 2007 to 2014. JAMA Surg. 2018; 154(3):225-231. PMC: 6439638. DOI: 10.1001/jamasurg.2018.4602. View

18.

Kahn A, Lomax S, Bajalia E, Ball C, Thiel D . Utility of the Aortic-Lesion-Attenuation-Difference (ALAD) and Peak Early-Phase Enhancement Ratio (PEER) to differentiate benign from malignant renal masses. Can J Urol. 2020; 27(4):10278-10284. View

19.

Gupta M, Alam R, Patel H, Semerjian A, Gorin M, Johnson M . Use of delayed intervention for small renal masses initially managed with active surveillance. Urol Oncol. 2018; 37(1):18-25. DOI: 10.1016/j.urolonc.2018.10.001. View

20.

McGillivray P, Ueno D, Pooli A, Mendhiratta N, Syed J, Nguyen K . Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) Classifier. Eur Urol. 2020; 79(1):107-111. PMC: 8939926. DOI: 10.1016/j.eururo.2020.09.017. View